© Reuters. FILE PHOTO: A medical worker handles a vial of the Pfizer-BioNTech Covid-19 vaccine at the Korian Samarobriva Ehpad (care home centre for ederly people) in Amiens, as the spread of the coronavirus disease (COVID-19) continues in France, January 7, 2021.
BERLIN (Reuters) -France is delaying an EU order for 1.8 billion doses of the BioNTech/Pfizer COVID-19 vaccine planned for the next two years, a German newspaper said on Friday, citing EU diplomats, but Paris said it backed the contract and was just asking questions.
In its report, German daily Die Welt said the reason for Paris’ hesitation was unclear, but diplomats had speculated that it might want French companies to play a bigger part in vaccine production.
At recent meetings of European Union ministers about vaccine orders, French representatives held up decision-making by posing technical questions and requests for clarifications, Die Welt reported.
Asked about the report, a spokesman for France’s Industry Ministry told Reuters: “Contrary to what has been reported, France has officially backed the (vaccine) contract within the formal European Commission framework.”
“We are asking common sense questions with regard to the public health challenges we are facing.”
Due to massive global demand for booster doses as well as vaccines for young people, EU governments fear that they may be too late and lose out on the order.
“That would be a disaster for which France would be responsible,” Die Welt quoted one diplomat as saying.
The EU has lagged countries such as Britain and the United States in getting its citizens vaccinated against COVID-19, causing tensions within the 27-nation bloc and prompting criticism of political leaders.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.